Drug Profile
Entecavir extended release - Aucta Pharmaceuticals
Alternative Names: Entecavir XRLatest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Aucta Pharmaceuticals
- Class Antivirals; Cyclopentanes; Hypoxanthines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors; RNA-directed DNA polymerase inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in Australia (PO, Tablet)
- 20 Jun 2018 Aucta Pharmaceuticals completes a phase I trial in Hepatitis B (In volunteers) in Australia (PO) (NCT03239353)
- 11 Aug 2017 Aucta Pharmaceuticals plans a phase I trial in Healthy volunteers in China (NCT03239353)